

approval for purposes of final publication; to transmit non-routine recommendation packages to the Office of the Secretary, together with any supplemental policy analysis, within established timeframes; to prepare nomination slates for Task Force member appointments, including maintaining a reserve candidate pool and administering expedited selection procedures; to administer vacancy and acting authority designations within relevant AHRQ components in accordance with applicable law; and to implement and operationalize the USPSTF supervisory Standard Operating Procedure (SOP), including associated reporting and compliance activities.

Notwithstanding the authorities delegated herein, the Secretary retains the authority to appoint and remove Task Force members; to review and take final action on non-routine Task Force recommendations; to make any determination to withhold concurrence on Task Force recommendations; and to approve any material modifications to the supervisory framework governing the Task Force. These functions are reserved to the Secretary and may not be delegated.

This delegation shall be exercised in accordance with applicable Department policies, procedures, and guidelines. The authority delegated herein may not be redelegated. The Secretary retains the authority to promulgate regulations and to submit reports to Congress.

This delegation supersedes all prior delegations of authority relating to the administration, support, or supervision of the U.S. Preventive Services Task Force.

This delegation is effective immediately upon signature. I hereby affirm and ratify any actions taken by the Director of AHRQ, Roger D. Klein, or his subordinates that involved the exercise of the authorities delegated herein prior to the effective date of the delegation.

Dated: May 13, 2026.

Robert F. Kennedy, Jr.,
Secretary.

[FR Doc. 2026-09841 Filed 5-15-26; 8:45 am]

BILLING CODE 4160-90-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as

amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Topics in Substance Use Pharmacology.

Date: June 8, 2026.

Time: 1:00 p.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Shiv A. Prasad, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, shiv.prasad@nih.gov.

Name of Committee: Oncology 2—Translational Clinical Integrated Review Group; Therapeutic Immune Regulation Study Section.

Date: June 22, 2026.

Time: 8:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Yue Wu, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 803C Bethesda, MD 20892, (301) 867-5309, wuy25@csr.nih.gov.

Name of Committee: Emerging Technologies and Training Neurosciences Integrated Review Group; Neuro Informatics, Computational and Data Analysis Study Section Neuro Informatics, Computational and Data Analysis.

Date: June 22–23, 2026.

Time: 8:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Aurea D. De Sousa, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5186 Bethesda, MD 20892, (301) 827-6829, aurea.desousa@nih.gov.

Name of Committee: Emerging Technologies and Training Neurosciences Integrated Review Group; Imaging and Bioengineering Technology for Visual Systems Study Section.

Date: June 22–23, 2026.

Time: 8:30 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Susan Gillmor, Ph.D., Scientific Review Officer, National Institutes of Health, Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD 20892, 240-762-3076, susan.gillmor@nih.gov.

Name of Committee: Applied Therapeutics for Cancer Integrated Review Group; Mechanisms of Cancer Therapeutics C Study Section.

Date: June 22, 2026.

Time: 8:30 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Gloria Huei-Ting Su, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301-496-0465, gloria.su@nih.gov.

Name of Committee: Vascular and Hematology Integrated Review Group; Integrative Vascular Physiology and Pathology Study Section.

Date: June 22, 2026.

Time: 9:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Manoj Kumar Valiyaveetil, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Bethesda, MD 20817, (301) 402-1616, manoj.valiyaveetil@nih.gov.

Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Analytics and Statistics for Population Research Panel A Study Section.

Date: June 22–23, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Emily M. Kilroy, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Bethesda, MD 20817, (301) 594-0813, kilroyem@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Training and Career Development: Neurosciences, Development, and Aging.

Date: June 22, 2026.

Time: 10:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Laurent Taupenot, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1009B, MSC 7850 Bethesda, MD 20892, (301) 435-1203, laurent.taupenot@nih.gov.

Name of Committee: Interdisciplinary Molecular Sciences and Training Integrated Review Group; Cellular and Molecular Technologies Study Section.

Date: June 22–23, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Tatiana V. Cohen, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5213, Bethesda, MD 20892, 301-455-2364, tatiana.cohen@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: May 13, 2026.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026-09852 Filed 5-15-26; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, National Institute of Biomedical Imaging and Bioengineering.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended, for the review, discussion, and evaluation of individual intramural

programs and projects conducted by the National Institute of Biomedical Imaging and Bioengineering, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors, National Institute of Biomedical Imaging and Bioengineering.

Date: June 15–16, 2026.

Open: June 15, 2026, 9:00 a.m. to 9:30 a.m.

Agenda: Call to order and opening remarks from the Scientific Director; Remarks from the NIBIB Institute Director.

Address: Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Room 610, Bethesda, MD 20892.

Meeting Format: In Person.

Closed: June 15, 2026, 9:30 a.m. to 5:00 p.m.

Agenda: Review of confidentiality & conflict of interest procedures; Review and evaluate qualifications, performance, and competence of individual investigators.

Address: Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Room 610, Bethesda, MD 20892.

Meeting Format: In Person.

Closed: June 16, 2026, 9:30 a.m. to 1:30 p.m.

Agenda: Review and evaluate qualifications, performance, and competence of individual investigators.

Address: Hyatt Regency Bethesda, 7400 Wisconsin Ave, Bethesda, MD 20814.

Meeting Format: In Person.

Contact Person: Richard D. Leapman, Ph.D., Intramural Scientific Director, National Institute of Biomedical Imaging, and Bioengineering, National Institutes of Health, Building 13, Rm 3E 73, Bethesda, MD 20892, 301-496-2599, leapmanr@mail.nih.gov.

Dated: May 12, 2026.

Margaret N. Vardanian,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026-09865 Filed 5-15-26; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOMELAND SECURITY

U.S. Customs and Border Protection

Fee for Fingerprints Collected by CBP

AGENCY: U.S. Customs and Border Protection, DHS.

ACTION: General notice.

SUMMARY: This notice announces that U.S. Customs and Border Protection (CBP) will begin collecting a fee for fingerprints collected by CBP from applicants seeking unescorted access to CBP security areas at airports. CBP collects fingerprints from applicants when the applicant submits a paper

application or when the applicant is an eBadge applicant for whom CBP has not received fingerprints from the Transportation Security Administration (TSA) or the fingerprints CBP receives from TSA are unreadable or unusable. The fee is the total of the current Federal Bureau of Investigation (FBI) user fee for conducting fingerprint checks and the CBP administrative processing fee.

DATES: CBP will begin collecting the fee described in this notice after June 17, 2026.

FOR FURTHER INFORMATION CONTACT: Guy Cange, Branch Chief, Traveler Entry Program, Office of Field Operations, U.S. Customs and Border Protection, by telephone at (202) 403-4176, or email at guy.h.cange@cbp.dhs.gov.

SUPPLEMENTARY INFORMATION:

Background

The Department of Homeland Security (DHS) is responsible for securing the borders, territorial waters, ports, terminals, waterways, and air, land, and sea transportation systems of the United States. See Homeland Security Act of 2002, Public Law 107-296, sec. 402, 116 Stat. 2135, 2177-78, as amended (6 U.S.C. 202). Within DHS, two components, U.S. Customs and Border Protection (CBP) and the Transportation Security Administration (TSA), have responsibilities supporting this mission by ensuring security at airports of entry. Specifically, CBP and TSA regulations provide for the designation of secured areas in airports as well as the requirements and procedures for obtaining and maintaining access to such areas.

The CBP security area regulations are set forth in subpart S of part 122 of title 19 of the Code of Federal Regulations (CFR). CBP security areas, or “Customs security areas,” are defined as the Federal Inspection Services (FIS) areas at airports accommodating international air commerce designated for processing passengers, crew, their baggage and effects arriving from, or departing to, foreign countries, as well as the aircraft deplaning and ramp area and other restricted areas designated by the port director. See 19 CFR 122.181 (defining the term “Customs security area”); 19 CFR 101.1 (defining the term “Customs” to mean CBP). Generally, persons located at, operating out of, or employed by any airport accommodating international air commerce who have unescorted access to a CBP security area must openly display or produce upon demand an approved access seal. 19 CFR 122.182(a). The requirements for the application for a CBP access seal